A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com

Key Inclusion Criteria

Diagnosis of advanced melanoma
Prior treatment in a prespecified prior/parent ipilimumab study
Men and women 18 years of age and older

First Reinduction:

No unacceptable toxicity (except select reversible immune-related adverse events) requiring ipilimumab discontinuation
Had experienced documented progressive disease after expanded clinical benefit

Extended Maintenance

Received ipilimumab at any dose in a parent study
Achieved expanded clinical benefit at the time of entry to current study

Follow-up:

Received ipilimumab at any dose in a closing parent study
Deemed ineligible for reinduction or extended maintenance treatment or refused treatment as reinduction or extended maintenance at the time of screening in the current study, but consented to follow-up

Key Exclusion Criteria

Prior treatment with a CD137 agonist or a cytotoxic T-lymphocyte antigen 4 inhibitor or agonist, other than ipilimumab
Primary ocular or mucosal melanoma